So-Young: Turning Positive On Sales Beat And Attractive Valuations (Rating Upgrade)

So-Young International (NASDAQ:SY) received an analyst upgrade to "Buy" following its Q2 2025 results, which saw revenue of CNY 0.38 billion beat consensus by 5% and grow 27% QoQ, primarily driven by its successful strategic pivot to the SY Clinic division whose sales quintupled year-over-year. Despite a widened net loss of CNY 0.031 billion due to aggressive network expansion and a subsequent 23% stock price decline, the analyst views the sell-off as an overreaction, creating an attractive entry point given the company's strong business transformation, appealing valuation at 1.0x forward EV/S compared to peers, and continued clinic expansion with improving cash flow break-even rates.

Analysis

So-Young International (SY) is demonstrating a successful strategic pivot from its legacy online platform to a direct-to-consumer model via its "SY Clinic" branded aesthetic centers. The company's Q2 2025 revenue of CNY 0.38 billion surpassed consensus estimates by 5% and grew 27% sequentially, driven by the SY Clinic division's sales quintupling year-over-year to CNY 144 million. This growth in the new segment, which now constitutes 38% of total revenue, effectively counteracted a 36% YoY decline in the legacy information services business. Despite this top-line outperformance, the market reacted negatively to a wider-than-expected net loss of CNY 0.031 billion, triggering a 23% drop in the share price. The losses are attributed to aggressive investments in network expansion—the company grew its clinic count to 29 and plans an additional 21 by year-end. Encouragingly, two-thirds of clinics achieved operating cash flow break-even by the end of Q2, and the division's gross margin improved 500 basis points quarter-over-quarter, signaling progress towards profitability. The resulting sell-off has compressed the company's valuation to a 1.0x forward Enterprise Value-to-Sales multiple, a notable discount to its historical average of 1.3x and peers trading at 1.6x to 2.0x.

Key Decisions for Investors

• The 23% post-earnings decline may present a tactical entry point for investors who believe the successful strategic pivot and top-line growth outweigh the current, investment-driven net losses.
• Investors should closely monitor the rate of new clinic openings against the company's year-end target and track progress toward operating profitability, as these are the key catalysts for the bull thesis.
• Consider the valuation gap, as SY's 1.0x forward EV/S multiple offers a significant discount to both historical levels and peers, suggesting potential for a valuation re-rating if execution on the expansion strategy remains on track.
• Acknowledge the primary risk that any slowdown in clinic expansion or further widening of losses could pressure the stock, as the market remains sensitive to profitability metrics.